The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients

Figures & data

Chart 1. The process diagram for patient selection and treatment.

Table 1. Characteristic of patients with AML according to FLT3 mutation type.

Characteristic	ITD pos	TKD mut	p-Value
No. of patients	130	28
Sex, n (%)
Male	61 (46.9%)	14 (50%)	0.767
Female	69 (53.1%)	14 (50%)
Age (y), median (range)	44 (19–59)	40 (20–60)	0.533
AML WHO classification, n (%)
M0	3 (2.3%)	0 (0%)	0.259
M1	20 (15.4%)	1 (3.6%)
M2	39 (30%)	8 (28.6%)
M4	22 (16.9%)	9 (32.1%)
M5	40 (30.8%)	10 (35.7%)
M7	6 (4.6%)	0 (0%)
Blood routine, median (range)
WBC count, ( × 10^9/l)	59.84 (1–441.46)	30.04 (3.69–257)	0.197
Hemoglobin, ( × g/l)	82 (36–147)	91 (61–130)	0.148
Platelet count, ( × 10^9/l)	42 (4–587)	43 (7–134)	0.373
BM blasts, median	0.75 (18–97.5)	0.745 (23–95)	0.686
Cytogenetic, n (%)
Favorable risk	11 (8.5%)	4 (14.3%)	0.62
Intermediate risk	107 (82.3%)	22 (78.6%)
Adverse risk	12 (9.2%)	2 (7.1%)
Gene mutation, n (%)
Only ITD/TKD	56 (43.1%)	12 (42.9%)	0.067
With mutated NPM1	38 (29.2%)	8 (28.6%)
CEBPA	12 (9.2%)	0 (0%)
DNMT3A	4 (3.1%)	1 (3.6%)
CKIT	1 (0.8%)	3 (10.7%)
more than one gene	19 (14.6%)	4 (14.3%)
CR after the first course of treatment
Yes	60 (46.2%)	18 (64.3%)	0.082
No	70 (53.8%)	10 (35.7%)

Figure 1. Survival comparison of FLT3 mutated AML patients. A/B. Comparison of OS and RFS for ITD positive group and TKD positive group. C/D. Comparison of OS and RFS for allo-HSCT, ITD positive subgroup and allo-HSCT, TKD positive subgroup. E/F. Comparison of OS and RFS for CT, ITD positive subgroup and CT, TKD positive subgroup.

Figure 2. Efficacy of allo-HSCT in FLT3 mutated AML patients. A/B. Comparison of OS and RFS for allo-HSCT, ITD positive subgroup and others, ITD positive subgroup. C/D. Comparison of OS and RFS for allo-HSCT, TKD positive subgroup and others, TKD positive subgroup.

Figure 3. Efficacy of sorafenib in FLT3-ITD mutated refractory AML patients. A/B. Comparison of OS and RFS for CT subgroup and CT + Sora subgroup. C/D. Comparison of OS and RFS for allo-HSCT in CR subgroup and allo-HSCT + Sora in CR subgroup. E/F. Comparison of OS and RFS for allo-HSCT in NR subgroup and allo-HSCT + Sora in NR subgroup.